- Home
- CAC vs PRTA Comparison
CAC vs PRTA Comparison
Compare CAC & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAC | PRTA |
|---|---|---|
| Founded | 1875 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.5M | 595.9M |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | CAC | PRTA |
|---|---|---|
| Price | $43.09 | $10.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $47.33 | $18.86 |
| AVG Volume (30 Days) | 64.9K | ★ 594.1K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ 9.13 | N/A |
| EPS | ★ 3.49 | N/A |
| Revenue | ★ $215,172,000.00 | $11,786,000.00 |
| Revenue This Year | $44.50 | N/A |
| Revenue Next Year | $7.03 | $819.08 |
| P/E Ratio | $12.35 | ★ N/A |
| Revenue Growth | ★ 27.50 | N/A |
| 52 Week Low | $34.53 | $4.32 |
| 52 Week High | $47.55 | $17.66 |
Technical Indicators
Market Signals| Indicator | CAC | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 69.15 | 48.36 |
| Support Level | $41.38 | $10.14 |
| Resistance Level | $41.60 | $11.57 |
| Average True Range (ATR) | 1.16 | 0.58 |
| MACD | 0.29 | 0.00 |
| Stochastic Oscillator | 93.26 | 26.95 |
Price Performance
Historical ComparisonAbout CAC Camden National Corporation
Camden National Corporation is a banking solutions provider in the United States. Its core business is providing commercial banking products to individuals and corporates. Its consumer and commercial banking services entail services such as loans and deposits, savings and online banking, treasury management solutions and non-profit products to consumer, institutional, municipal, non-profit and commercial customers. The company also offers investment management and fiduciary services.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.